CIMAvax Lung Cancer Vaccine

Roswell Park Cancer Institute
Posted at 12:41 PM, Nov 22, 2016
and last updated 2016-11-22 12:41:49-05

Roswell Park is launching the first clinical trial in the United States to study the CIMAvax-EGF® vaccine, a lung cancer treatment that was developed in Cuba.

We are the only facility in the country that will offer this groundbreaking treatment.

The CIMAvax study is not yet open. But if you are found to be eligible, you will be placed on a waiting list and notified when the study opens.